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Background: The potential for an ultrasound-based screening programme for renal cell carcinoma
(RCC) to improve survival through early detection has been the subject of much debate. The prevalence
of ultrasound-detected asymptomatic RCC is an important first step to establishing whether a screening
programme may be feasible.
Methods: A systematic search of MEDLINE and Embase was performed up to March 2016 to identify
studies reporting the prevalence of renal masses and RCC. Two populations of patients were chosen:
asymptomatic individuals undergoing screening ultrasonography and patients undergoing ultrasono-
graphy for abdominal symptoms not related to RCC. A random-effects meta-analysis was performed.
Study quality was evaluated using a validated eight-point checklist.
Results: Sixteen studies (413 551 patients) were included in the final analysis. The pooled prevalence of
renal mass was 0⋅36 (95 per cent c.i. 0⋅23 to 0⋅52) per cent and the prevalence of histologically proven
RCC was 0⋅10 (0⋅06 to 0⋅15) per cent. The prevalence of RCC was more than double in studies from
Europe and North America than in those from Asia: 0⋅17 (0⋅09 to 0⋅27) versus 0⋅06 (0⋅03 to 0⋅09) per
cent respectively. Data on 205 screen-detected RCCs showed that 84⋅4 per cent of tumours were stage
T1–T2N0, 13⋅7 per cent were T3–T4N0, and only 2⋅0 per cent had positive nodes or metastases at
diagnosis.
Conclusion: At least one RCCwould be detected per 1000 individuals screened. Themajority of tumours
identified are early stage (T1–T2).
Paper accepted 2 February 2017
Published online in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.10523
Introduction
Overall survival from renal cell carcinoma (RCC) is
poor, with a 5-year age-standardized relative survival
rate of 47 per cent in the UK1. Half of all patients with
renal cancer present with asymptomatic disease and so
many cancers are detected late, with over one-quarter
of individuals diagnosed with RCC having evidence of
metastases at presentation2,3. Patients with metastases
have a 5-year age-standardized relative survival rate of
6 per cent, compared with 84 per cent in patients with stage
I disease1. Incidentally detected tumours are generally
smaller and are associated with improved survival relative
to symptomatic tumours, independent of tumour grade
and stage4,5.
A screening programme consisting of abdominal ultra-
sonography, potentially in a selected higher-risk popula-
tion, in theory could improve survival outcomes through
early detection and treatment of RCC. Previously, the
low prevalence of renal cancer in the general population
and relatively poorly understood natural history of renal
masses were considered major barriers to establishing a
cost-effective screening service6. More recently, there has
been a resurgence in interest in a screening programme for
RCC7. The established abdominal aortic aneurysm (AAA)
screening programme in men over the age of 65 years in
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the UK represents an ideal model to explore the possibility
of screening for RCC as there are similarities in risk factors
and mode of detection between RCC and AAA8. Further-
more, although a number of drugs for the treatment of
metastatic RCC are available, they are very expensive9–11.
It has been postulated that early detection of asymptomatic
RCC through a targeted national screening programme
may potentially downstage the disease, reducing the preva-
lence of metastatic tumours and associated expenditure
relating to systemic therapies.
Before consideration of a screening study for RCC,
it is essential to assess potential cost-effectiveness, by
assembling all relevant evidence on the incremental
costs and consequences of screening into an economic
model. One of the key parameters that will inform
cost-effectiveness is the prevalence of renal masses and
RCC in a screened population12; therefore, a systematic
review and meta-analysis was performed to determine
RCC prevalence.
Methods
Data sources and search strategy
The study protocol was registered on the PROSPERO
database (http://www.crd.york.ac.uk/PROSPERO/; CRD
42016036899) and the study conducted in accordance with
PRISMA guidelines13. A systematic literature search was
performed in MEDLINE (January 1976 to March 2016)
and Embase (January 1976 to March 2016) databases. Full
details of the keywords and subject headings used are avail-
able in Table S1 (supporting information). The reference
lists of all relevant articles were reviewed manually.
Inclusion and exclusion criteria
Study inclusion, data extraction and data quality assess-
ments were performed independently by two reviewers,
with discrepancies resolved by a third investigator. Full
inclusion and exclusion criteria are reported in Table S2
(supporting information). Studies were included in the
analysis if the prevalence of renal masses and/or RCC
was reported in asymptomatic individuals undergoing
abdominal ultrasonography (screening group), patients
undergoing abdominal ultrasonography for a medical
reason not related to RCC (incidental finding group) or
the study comprised a combination of both screened as
well as non-screened individuals (mixed group). Studies
were excluded if ultrasound imaging was performed in
individuals who did not represent a general adult popu-
lation or if patients had symptoms of renal cancer (flank
pain, abdominal mass, non-visible and/or visible haema-
turia). Patients undergoing ultrasonography for suspected
renal colic were also excluded as symptoms may have been
secondary to RCC rather than renal stones. Studies that
undertook ultrasound screening in individuals with familial
syndromes predisposing to RCC, or patients with renal
transplant or end-stage renal disease were also excluded
from the analysis.
Study quality assessment
A validated checklist was used to assess the quality of
studies reporting the prevalence of renal masses in a
screening population, with studies scored out of a total
of 8 points14. Item 6 on the checklist evaluates whether
the studies reported the participation rate of individ-
uals invited to attend screening. Studies reporting the
prevalence of incidental renal masses in patients undergo-
ing ultrasonography for a non-urological complaint were
assessed on a modified 7-point checklist, as item 6 was no
longer a valid item in this group. Item 3 on the check-
list evaluates whether the study sample size was suffi-
cient to estimate prevalence with an adequate level of con-
fidence and precision. Studies were awarded a point if
they included more than 5107 participants (Appendix S1,
supporting information)15,16. Study quality was used to
perform subgroup analysis. No studies were excluded from
the meta-analysis based on quality score or sample size.
Study outcomes
The primary study outcomes were the prevalence of solid
or complex cystic renal masses suspicious for RCC on
ultrasonography, and the prevalence and stage distribution
of histologically proven RCC in asymptomatic individuals.
The secondary outcome was the prevalence of other renal
and adrenal pathology. Preplanned subgroup analysis con-
sisted of study type (screening, mixed or incidental finding),
study geographical region of origin, publication year and
study quality. The prevalence of RCC by established risk
factors such as age, sex, hypertension, smoking and BMI
was assessed.
Statistical analysis
The meta-analysis was performed on the double arcsine
transformation (Appendix S2, supporting information)17
for each proportion, using the generic inverse-variance
method. The double arcsine transformation stabilizes
the variance and is particularly useful for proportions
that are at the extremes of the 0 to 1 range, as is the
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 Other imaging modality n = 21
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n = 96
Records screened after duplicates removed
n = 2658
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n = 2562
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qualitative synthesis
n = 16
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quantitative synthesis
(meta-analysis)
n = 16
Fig. 1 PRISMA flow diagram showing search strategy
case for an uncommon condition such as RCC17. In this
case, asymmetrical confidence intervals are created to
avoid reporting a prevalence in the negative range. As
such, it is not appropriate to use funnel plots to assess for
publication bias, as the typical funnel shape relies on sym-
metry of confidence intervals. Heterogeneity was assessed
using the χ2 test and the I2 (Cochran’s Q) statistic. The
pooled prevalence was calculated using a random-effects
model as there was significant heterogeneity between
studies. Meta-regression was used to assess the association
between study characteristics (study type, size, publication
year and geographical region) and the prevalence of RCC.
P< 0⋅050 was considered statistically significant. The
statistical analysis was performed using Stata® version 12.0
(Stata Corp, College Station, Texas, USA).
Results
Data retrieval and study quality
Following exclusion of duplicates, the search yielded
2658 articles. Sixteen studies were included in the final
meta-analysis for renal masses (413 551 individuals) (Fig. 1
and Table 1)8,16,18–31. The median quality score for studies
in the screening and mixed groups was 4 (range 3–6) of 8,
whereas studies in the non-screening group only achieved
a median score of 1⋅5 (range 1–3) of 7 (Table S3, supporting
information). All studies were observational, consisting of
one study arm alone (no non-screening comparator), and
none used a random sampling method. Only one study22
commented on the participation rate of individuals invited
to attend screening. None of the studies reported 95 per
cent confidence intervals for point estimates of prevalence,
despite the fact that this was an item on the quality assess-
ment checklist (although this is readily calculable, given
knowledge of the sample size). Three studies16,26,30 did not
clearly state ultrasound criteria used to define a suspicious
renal mass and three21,25,29 further studies included only
solid (rather than complex cystic) masses in this definition.
Five studies23,26–29 reported data on the prevalence of
renal masses, but no histological data were available, so
these studies were excluded from the analysis of the preva-
lence of histologically proven RCC. All studies reporting
the prevalence of histologically proven RCC were based
on operative (rather than biopsy) specimens.
Primary outcomes
The pooled prevalence of renal masses was 0⋅36 (95 per
cent c.i. 0⋅23 to 0⋅52) per cent (Fig. 2) and that of histolog-
ically proven RCC was 0⋅10 (0⋅06 to 0⋅15) per cent (Fig. 3).
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Table 1 Characteristics of included studies
Reference Country Data collection dates Sample size Sample recruitment Age (years)* Male sex (%)
Fujii et al.18 Japan April 1985 to
March 1991
17941 Asymptomatic individuals,
employee health check-up
53 (21–85)† 72
Spouge et al.19 Canada 6-month interval,
not specified
1000 Asymptomatic individuals,
employee health check-up
for business executives
46⋅2 (29–63) 91
Spouge et al.19 (2) Canada 2⋅5-year interval,
not specified
7925 Asymptomatic individuals,
employee health check-up
for business executives
n.r. n.r.
Mihara et al.16 Japan August 1983 to
March 1996
219640 Asymptomatic screening of
general population
(29–70) n.r.
Tsuboi et al.20 Japan January 1993 to
June 1997
60604 Asymptomatic individuals,
health check-up for
general population
(15–96) 67
Mizuma et al.21 Japan February 1990 to
December 1995
16 024 Asymptomatic individuals,
health check-up for
general population
47 (25–84) 58
Filipas et al.22 Germany December 1996 for
13 months and
January 1998 for
13 months
9959 Asymptomatic screening of
general population,
individuals aged
>40 years
61 (40–94) 49
Malaeb et al.8 USA 1993 to 1997 6678 Asymptomatic screening of
veterans (in conjunction
with AAA screening)
66⋅2 (50–79) 97
Mosharafa23 8 Middle Eastern
countries
January 2005 to
December 2005
8551 Asymptomatic individuals,
health check-up for
general population
43⋅5(13⋅9)‡ 70
Tosaka et al.24 Japan 1982 to 1988 41364
(20 897
screening,
20 467
non-screening)
Mixed: asymptomatic
individuals (part of health
check-up) and patients
undergoing abdominal
ultrasonography for
non-urological complaint
n.r. n.r.
Haliloglu et al.25 Turkey March 1995 to
February 2008
18 203 Mixed: asymptomatic
individuals (part of health
check-up) and patients
having ultrasound for
LUTS
55 (33–90) 64
Fields and
Calvert-Hill26
USA n.r. 500 Abdominal ultrasonography
for non-urological
complaint
n.r. n.r.
Bodner et al.27 USA n.r. 86 Patients with spinal cord
injury, no urological
symptoms
41⋅7 99
Al-Durazi et al.28 Bahrain January 2001 to
December 2001
100 Men with acute retention
secondary to BPH
67 (54–96) 100
Belani et al.29 USA 3months, not
specified
600 Abdominal ultrasonography
for non-urological
complaint
53 (18–95) 32
Heikkinen et al.30 Finland January 1993 to
January 1994
400 Patients undergoing
investigations for
dyspepsia
Endoscopy-
negative: 55⋅8
Endoscopy-
positive:
58⋅3
38
Patel et al.31 UK April 1994 to
February 2007
3976 Men with LUTS 65 (15–91) 100
*Values are mean (range) unless indicated otherwise; values are †median (range) and ‡mean(s.d.). n.r., Not reported; AAA, abdominal aortic aneurysm;
LUTS, lower urinary tract symptoms; BPH, benign prostatic hyperplasia.
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Reference
Screening population
Fujii et al.18
Spouge et al.19
Mihara et al.16
Tsuboi et al.20
Mizuma et al.21
Filipas et al.22
Malaeb et al.8
Mosharafa23
45 of 17941
21 of 1000
638 of 219640
97 of 60604
24 of 16024
13 of 9959
30 of 6678
7 of 8551
355 of 41364
81 of 18203
7 of 500
1 of 86
1 of 100
7 of 600
3 of 400
18 of 3976
Subtotal (I2 = 93·76%, P = 0·00)
Incidental finding
Fields and Calvert-Hill26
Bodner et al.27
Al-Durazi et al.28
Belani et al.29
Heikkinen et al.30
Patel et al.31
Subtotal (I2 = 50·15%, P = 0·07)
Heterogeneity between groups: P < 0·001
Overall (I2 = 96·41%, P = 0·00)
Mixed
Tosaka et al.24
Haliloglu et al.25
Subtotal (I2 = 99·11%, P = 0·00)
Proportion with
renal mass
1·5 2·0 2·51·0
Prevalence (%)
0·50
Prevalence (%)
8·31
5·16
8·59
8·52
8·27
8·07
7·83
7·99
62·75
3·68
0·98
1·12
4·07
3·22
7·37
20·45
100·00
8·48
8·31
16·79
0·25 (0·19, 0·34)
2·10 (1·38, 3·19)
0·29 (0·27, 0·31)
0·16 (0·13, 0·20)
0·15 (0·10, 0·22)
0·13 (0·08, 0·22)
0·45 (0·31, 0·64)
0·08 (0·04, 0·17)
0·25 (0·17, 0·35)
1·40 (0·68, 2·86)
1·16 (0·21, 6·30)
1·00 (0·18, 5·45)
1·17 (0·57, 2·39)
0·75 (0·26, 2·18)
0·45 (0·29, 0·71)
0·73 (0·31, 1·30)
0·36 (0·23, 0·52)
0·86 (0·77, 0·95)
0·44 (0·36, 0·55)
0·72 (0·65, 0·79)
Weight (%)
Fig. 2 Forest plot demonstrating the pooled prevalence of suspicious renal masses detected by ultrasonography, generated by a
random-effects meta-analysis, for three subgroups: screening population, incidental finding and mixed. Prevalence is shown with 95 per
cent confidence intervals
Significant study heterogeneity was noted for both out-
comes (χ2 = 327⋅60, 15 d.f., P< 0⋅001, I2 = 96 per cent and
χ2 = 112⋅62, 11 d.f., P< 0⋅001, I2 = 91 per cent).
Of the 11 studies investigating the prevalence of
screen-detected RCC, a wide variation in the method
used for reporting the size and stage of the tumours was
noted. Only three studies8,16,22 reported data on the TNM
staging of the detected RCCs; two of these used the TNM
1992 classification32 and one used TNM 199733. Two
studies19,24 reported staging by Robson’s classification34
and three studies20,21,25 reported individual tumour size
but not tumour stage. Differences in reporting of data
limited the ability to pool results on the size and stage
of screen-detected RCC, and so three different group-
ing methods were used (Table S4, supporting information).
Data on 66 cancers from four studies8,21,22,25 were pooled to
reveal that 45 per cent of screen-detected cancers were 4 cm
or smaller in size, 41 per cent RCCs were between 4 and
7 cm, and only 14 per cent larger than 7 cm. Similarly, data
on 185 screen-detected RCCs from two further studies16,20
demonstrated that 80⋅0 per cent of tumours were 5 cm
or smaller in size. Pooling data on 205 screen-detected
RCCs from three studies8,16,22 showed that 84⋅4 per cent
of tumours were category T1–T2 N0, 13⋅7 per cent were
T3–T4 N0, and only 2⋅0 per cent had positive lymph nodes
or metastases at diagnosis (TNM 1992 classification)32.
Secondary outcomes
A number of additional renal and adrenal pathologies were
identified among the studies (Table S5, supporting informa-
tion). Of note, Mihara and colleagues16 reported detection
of an additional five (prevalence 0⋅002 per cent) malignant,
non-RCC kidney lesions in addition to the RCCs (preva-
lence 0⋅086 per cent). Owing to heterogeneity of reported
data, only the prevalence of asymptomatic hydronephro-
sis and renal stones were pooled in a meta-analysis. The
pooled prevalence of hydronephrosis was 0⋅48 (0⋅21 to
0⋅87) per cent (χ2 = 76⋅75, 5 d.f., P< 0⋅001, I2 = 95 per
© 2017 BJS Society Ltd www.bjs.co.uk BJS 2017; 104: 648–659
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Reference
Proportion with
RCC
0·50 0·75
Prevalence (%)
0·250
Prevalence (%) Weight (%)
Screening population
Fujii et al.18
Spouge et al.19
Spouge et al.19 (2)
Mihara et al.16
Tsuboi et al.20
Mizuma et al.21
Filipas et al.22
Malaeb et al.8
20 of 17941 0·11 (0·07, 0·17)
0·40 (0·16, 1·02)
0·29 (0·19, 0·44)
0·09 (0·07, 0·10)
0·02 (0·01, 0·04)
0·04 (0·02, 0·08)
0·11 (0·06, 0·20)
0·22 (0·14, 0·37)
0·11 (0·06, 0·17)
9·93
3·24
8·60
11·17
10·86
9·78
9·04
8·24
70·87
10·66
9·94
20·60
1·57
6·96
8·52
100·00
0·05 (0·03, 0·07)
0·20 (0·14, 0·27)
0·08 (0·06, 0·11)
0·25 (0·04, 1·40)
0·08 (0·03, 0·22)
0·05 (0·00, 0·16)
0·10 (0·06, 0·15)
4 of 1000
23 of 7925
189 of 219640
13 of 60604
6 of 16024
11 of 9959
15 of 6678
19 of 41364
36 of 18203
1 of 400
3 of 3976
Subtotal (I2 = 92·23%, P = 0·00)
Incidental finding
Heikkinen et al.30
Patel et al.31
Subtotal (I2 = 98·89%, P = 0·00)
Heterogeneity between groups: P = 0·476
Overall (I2 = 90·75%, P = 0·00)
Mixed
Tosaka et al.24
Haliloglu et al.25
Subtotal (I2 = 98·89%, P = 0·00)
Fig. 3 Forest plot demonstrating the pooled prevalence of histologically proven renal cell carcinoma (RCC) detected by
ultrasonography, generated by a random-effects meta-analysis, for three subgroups: screening population, incidental finding and mixed.
Prevalence is shown with 95 per cent confidence intervals
Table 2 Subgroup analysis for the pooled prevalence of renal
masses and histologically proven renal cell carcinoma
Prevalence of
renal masses (%)
Prevalence of
histologically
proven RCC (%)
Overall pooled prevalence 0⋅36 (0⋅23, 0⋅52) 0⋅10 (0⋅06, 0⋅15)
Study publication year
Before 1999 0⋅67 (0⋅31, 1⋅13) 0⋅11 (0⋅06, 0⋅18)
2000 and 2004 0⋅17 (0⋅07, 0⋅30) 0⋅08 (0⋅02, 0⋅17)
2005 to present 0⋅32 (0⋅10, 0⋅67) 0⋅12 (0⋅04, 0⋅23)
Study quality
Quality score≥4 0⋅28 (0⋅19, 0⋅40) 0⋅12 (0⋅07, 0⋅18)
Quality score<4 0⋅55 (0⋅22, 0⋅99) 0⋅03 (0⋅00, 0⋅09)
Geographical region
Asia 0⋅30 (0⋅14, 0⋅52) 0⋅06 (0⋅03, 0⋅09)
Europe and North America 0⋅70 (0⋅31, 1⋅22) 0⋅17 (0⋅09, 0⋅27)
Middle East 0⋅16 (0⋅00, 0⋅66) 0⋅20 (0⋅14, 0⋅27)
Values in parentheses are 95 per cent confidence intervals. RCC, renal
cell carcinoma.
cent) (Fig. S1, supporting information) and the prevalence
of asymptomatic renal stones was 1⋅82 (0⋅59 to 3⋅64)
per cent (χ2 = 844⋅78, 9 d.f., P< 0⋅001, I2 = 100 per cent)
(Fig. S2, supporting information).
Subgroup analyses
The geographical region in which the study was under-
taken was the only subgroup that consistently affected the
prevalence of renal masses and histologically proven RCC
(Table 2). However, assessing the prevalence by study geo-
graphical region did not reduce heterogeneity. The preva-
lence of renal masses and RCC in studies from Europe and
North America was more than double that in studies from
Asia (renal mass: 0⋅70 (95 per cent c.i. 0⋅31 to 1⋅22) versus
0⋅30 (0⋅14 to 0⋅52) per cent respectively; RCC 0⋅17 (0⋅09
to 0⋅27) versus 0⋅06 (0⋅03 to 0⋅09) per cent). Geographi-
cal region was a significant determinant of the prevalence
of RCC in meta-regression (P= 0⋅002), but study type
and quality were not (P= 0⋅876 and P= 0⋅432 respectively)
(Table S6, supporting information). The effect of publica-
tion year, study type and study quality was not consistent
across the two outcomes.
The pooled prevalence of renal masses was higher in
the non-screening subgroup than the screening subgroup
(0⋅73 (0⋅31 to 1⋅30) versus 0⋅25 (0⋅17 to 0⋅35) per cent
respectively) (Fig. 2); however, this pattern was not noted
in terms of the prevalence of RCC, which was lower in
© 2017 BJS Society Ltd www.bjs.co.uk BJS 2017; 104: 648–659
Published by John Wiley & Sons Ltd
654 S. H. Rossi, R. Hsu, C. Blick, V. Goh, P. Nathan, D. Nicol et al.
the non-screening compared with the screening subgroup
(0⋅05 (0⋅00 to 0⋅16) versus 0⋅11 (0⋅06 to 0⋅17) per cent).
There were insufficient data to assess the impact of estab-
lished risk factors on the development of RCC, includ-
ing patient age, hypertension, smoking status and BMI.
Only five studies8,18,20–22 reported sufficient data to allow
calculation of the prevalence of RCC by sex. The pooled
prevalence was higher in men than women (0⋅09 (0⋅03 to
0⋅18) versus 0⋅01 (0⋅00 to 0⋅05) per cent).
Discussion
Early detection and screening for cancer has been iden-
tified as a key priority for the National Health Service,
with increased resource allocation and media coverage35.
Although the UK National Screening Committee has
released recommendations regarding screening for
colorectal, breast, prostate, ovarian and lung cancer,
screening for RCC has yet to be discussed as there are
currently incomplete data, with relatively little research
published in the literature over the past decade2,36. Data
on the prevalence of RCC in asymptomatic individuals
undergoing abdominal ultrasonography are lacking, but
are essential to inform an economic evaluation of the
cost-effectiveness of an ultrasound-based screening pro-
gramme. Here, a pooled prevalence of renal masses was
0⋅36 (95 per cent c.i. 0⋅23 to 0⋅52) per cent, with a pooled
prevalence of histologically proven RCC of 0⋅10 (0⋅06 to
0⋅15) per cent. Current National Cancer Intelligence Net-
work data37 suggest that, although 44 per cent of patients
diagnosed with RCC have stage disease 1 at presentation,
only 10 per cent have stage II tumours, with over 25
per cent having metastases. The present meta-analysis
showed that 84⋅4 per cent of screen-detected tumours
were stage T1–T2 N0, 13⋅7 per cent were T3–T4 N0,
and only 2⋅0 per cent had positive nodes or metastases at
diagnosis, suggesting a potential favourable stage shift in
screen-detected disease.
It is anticipated that focused screening renal ultra-
sonography will lead to detection of other benign and
malignant renal and adrenal abnormalities. The preva-
lence of screen-detected hydronephrosis was estimated to
be 0⋅48 (0⋅21 to 0⋅87) per cent and that of renal stones
1⋅82 (0⋅59 to 3⋅64 per cent). Unfortunately, there were
insufficient data to estimate the pooled prevalence of
benign masses of the renal fossa, such as angiomyolipoma
and oncocytoma, or the prevalence of renal cysts, the
most common screen-detected renal pathology. The
prevalence of asymptomatic cysts is estimated to be 30
per cent in individuals aged over 70 years38. A proportion
of screen-detected cysts may require further imaging,
discussion with a specialist and, potentially, treatment.
An evaluation of a screening programme for RCC must
take into consideration the impact of incidentally detected
benign renal lesions on patients and health services. There
is a potential for false-positive results and overdiagnosis
of slow-growing small renal masses (SRM). Currently,
15–30 per cent of SRM are found to be benign follow-
ing surgical excision39–41. Advances in determination
of the aetiology of SRM, with increased use and better
interpretation of renal biopsy, may reduce these rates in
future42. Up to one-third of small renal cancers exhibit
aggressive potential (rapid growth or doubling time less
than 12 months), with the remainder growing slowly
or remaining stable in size43,44. It is anticipated that, in
future, the development of non-invasive modalities, such as
measurement of urinary biomarkers, will allow improved
discrimination between benign and malignant SRM (with
further differentiation between indolent and aggressive
RCC), enabling personalized treatment strategies and
reducing overtreatment45.These considerations may be
offset further by the potential benefit derived from early
detection of other malignancies within the renal fossa
(including adrenal and upper urinary tract urothelial cell
cancers, renal secondary metastases, renal carcinoid, sar-
coma and lymphoma). Spouge and colleagues19 reported
the prevalence of these combined malignancies as 0⋅2 per
cent, whereas Mizuma et al.21, Malaeb and colleagues8 and
Patel and co-workers31 all reported a prevalence of 0⋅03
per cent. These rates vary considerably, and insufficient
data were available for meta-analysis. Further studies
are needed to quantify this and to estimate the potential
impact on health services.
It is likely that this meta-analysis underestimated the
true prevalence of histologically proven RCC. Several
studies8,16,20,22 reported a higher prevalence of suspected
RCC; however, owing to patient loss to follow-up or con-
traindications to surgery, histological confirmation was
only available in a portion of these. For example, Malaeb
and colleagues8 screened 6678 individuals with ultrasono-
graphy and confirmatory CT demonstrated 22 solid renal
masses suspicious for RCC; however, histology was avail-
able for only 15 of these, potentially underestimating the
true prevalence of malignancy. Furthermore, only half of
the studies included in the meta-analysis represented a
European or North American population, with the remain-
der originating from Asia or the Middle East. The results
suggest that there is significant variability between the
prevalence of screen-detected RCC in different geograph-
ical areas, in keeping with known epidemiological data46.
The prevalence of RCC in studies originating from Europe
and North America was more than double that in Asia.
Another factor that may have contributed to a potential
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underestimation of the true prevalence of RCC is the
young age of the screening study participants. Only one
of eight screening studies reported a participant mean age
over 65 years and five studies included individuals aged
less than 30 years. Young patients with RCC are at greater
risk of familial syndromes predisposing to cancer; how-
ever, owing to lack of patient-level data, it was not possi-
ble to exclude young participants from the analysis by age.
In addition, the included studies were published between
1985 and 2010, with over 13 of 16 published before 2006.
Such factors restrict the applicability of these results to the
population of interest in the UK, and highlight the need
for more high-quality research in a contemporary Western
population. Obesity and older age are established risk fac-
tors for the development of RCC47,48 and, with the growing
obesity epidemic and ageing population, the incidence of
RCC is expected to rise in the future.
This meta-analysis included relatively low-quality stud-
ies. The retrospective design and substantial rates of loss
to follow-up should all be taken into consideration when
interpreting the results. In addition, there were discrepan-
cies in the ultrasound criteria used to define a renal mass
in different studies. Importantly, none of the studies com-
pared a screening intervention with a non-screening group
or used a random sampling method to select study partic-
ipants. In addition, methods used to recruit participants
may also introduce bias within the screening group. For
example, two studies18,19 offered abdominal ultrasonogra-
phy to asymptomatic individuals as part of an employee
health check-up, rather than screening individuals through
a population registry. The inclusion of studies assessing the
prevalence of renal cancer in patients undergoing abdomi-
nal ultrasound examination for a medical reason not related
to kidney cancer (incidental finding group) may have intro-
duced heterogeneity in the data. These smaller studies
are also more prone to potential publication bias. How-
ever, neither study type nor quality score were found to
be significant factors in meta-regression, and heterogeneity
remained high even when only screening population stud-
ies were pooled. The persistent heterogeneity may in part
be attributed to differences in study design and patient pop-
ulations. The included studies reported only limited data
on the prevalence of renal cancer by established risk fac-
tors, precluding any formal analysis. Although, as expected,
the prevalence of RCC was found to be higher in male
compared with female patients, it is likely the estimate
of effect size is inaccurate owing to small sample sizes,
hindering conclusions regarding the potential for targeted
screening.
The results of this meta-analysis on the prevalence of
RCC detected by ultrasonography are broadly in keeping
with what would be expected from the data published
for screening using non-contrast CT. Two studies have
attempted to pool data from the literature to quantify the
prevalence of renal cancer in asymptomatic individuals, and
both of these used non-contrast CT rather than ultrasound
imaging as a screening tool. Fenton and Weiss49 calculated
the pooled prevalence of renal cancer in asymptomatic
American patients undergoing non-contrast screening CT
as 0⋅21 (95 per cent c.i. 0⋅14 to 0⋅28) per cent. Wernli
et al.50 estimated the pooled prevalence of renal masses
as 0⋅22 per cent in patients undergoing non-contrast CT
colonography, with a rate of 0⋅06 per cent in screened pop-
ulations and 0⋅42 per cent in non-screening populations.
Conversely, ultrasonography is known to be less sensitive
and specific than non-contrast CT for the detection of
renal cancers; ultrasound detection rates are dependent on
renal lesion size, a factor that would need to be consid-
ered in the design of a screening programme in terms of
frequency of ultrasonography51. Studies examining autop-
sies or cadaveric organ donors have estimated a prevalence
of RCC of 0⋅7–0⋅9 per cent (mean age of study partici-
pants 65 years)52,53. This is substantially higher than the
prevalence suggested by the present meta-analysis, rais-
ing once again the possibility that the true prevalence
of histologically proven RCC may have been underesti-
mated.
This meta-analysis suggests that screening 1000 indi-
viduals would result in four patients undergoing further
imaging of a renal mass, and that at least one of these
patients would be diagnosed with RCC. The clinical signif-
icance of these findings is best appreciated in the context of
other established screening programmes (Fig. 4). The NHS
AAA screening programme identifies ten men with an AAA
of 3 cm or larger for every 1000 individuals screened. How-
ever, only two men undergo elective surgery to repair a
large AAA following initial screening54. An additional six
individuals require elective surgery to repair a large AAA
following active surveillance over a 20-year interval55.
Results from the Bowel Cancer Screening Programme in
England56 have demonstrated that 1⋅6 colorectal cancers
are detected for every 1000 individuals screened using
guaiac-based faecal occult blood tests. An additional six
cases are detected with high-risk adenomatous polyps
requiring surveillance colonoscopy. The UK Breast Can-
cer Screening Programme57 breast cancer detection rate
is 8⋅3 per 1000 women screened. This number is much
higher than the projected values for RCC screening; how-
ever, it is estimated that 15–25 per cent of screen-detected
breast cancers are overdiagnosed58. Screening for RCC
may compare favourably with the established pro-
grammes for AAA and colorectal cancer, although intrinsic
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Fig. 4 Infographic delineating comparative detection ability of established UK screening programmes compared with screening for
renal cell carcinoma. The present meta-analysis suggests that screening 1000 individuals would detect at least one renal cell carcinoma.
Screening 1000 individuals detects 1⋅6 colorectal cancers, eight breast cancers and ten abdominal aortic aneurysms (AAAs) with a
diameter of at least 3 cm
differences underlying each screening programme and the
individual nature of each disease make direct comparisons
artificial.
In isolation, this meta-analysis is insufficient to support
or refute a screening programme for RCC and should
not replace a full consideration of the Wilson–Jungner
criteria59. A cost-effectiveness analysis is beyond the
scope of this paper, but should constitute an essen-
tial next step towards establishing the potential value
of screening.
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